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ABSTRACT
Objective: The main objective of this study was to prepare and evaluate the nanocrystal formulation of docetaxel.
Methods: Docetaxel nanocrystals were formulated to improve the water solubility. Docetaxel nanocrystals were prepared by nanoprecipitation 
method using Tween 80, egg lecithin, and povidone C-12 as stabilizers and poly(lactic-co-glycolic acid) (PLGA) as polymer in acceptable limits. A total 
of 16 formulations were prepared by changing stabilizer and polymer ratios. The prepared nanocrystals were characterized by particle size, zeta 
potential, crystalline structure, surface morphology, assay, saturation solubility, and in vitro drug release.
Results: Based on particle size, polydispersity index, and zeta potential data, four formulations were optimized. The formulation containing Tween 
80 as stabilizer has shown lowest particle size and better drug release than the formulations containing egg lecithin and povidone C-12 as stabilizers. 
The formulation containing Tween 80 and PLGA has shown still lower sized particles than the Tween 80 alone and exhibited prolonged sustained 
drug release. The release kinetics of formulations containing Tween 80 and PLGA followed zero-order release kinetics and formulations containing 
egg lecithin and povidone C-12 followed Higuchi diffusion (non-Fickian).
Conclusion: From the study, we concluded that as the type and concentration of stabilizer changed the size and shape of the crystals were also 
changed and the formulations showed sustained drug release with non-Fickian diffusion.
Keywords: Docetaxel, Nanocrystals, Tween 80, Egg lecithin, Povidone C-12, Poly(lactic-co-glycolic acid).
INTRODUCTION
Cancer is the main cause of death worldwide. Nanotechnology has 
a great approach to have a revolutionary impact on cancer diagnosis 
and therapy [1]. The use of different formulation techniques such as 
inclusion complexes, emulsions, microemulsions, micelles, liquid solids, 
liposomes, and microspheres was prevented due to poor physical 
stability, difficulty in scale-up, and inability to achieve high drug-loading 
problems [2]. Drug delivery through nanoparticles presents novel 
therapeutic opportunities for drugs that were previously unsuited to 
traditional oral or injectable drug formulations, allowing drugs to be 
delivered efficaciously while reducing side effects and shows better 
patient compliance [3].
Docetaxel is a semi-synthetic derivative comes under taxoid family [4]. 
It is an analog of paclitaxel which is extracted from the European yew 
tree (Taxus baccata L.). Being a microtubule-stabilizing agent, it 
inhibits microtubule disassembly causing inhibition of cell division and 
eventual cell death. Docetaxel is used to treat a number of cancers such 
as breast, ovarian, lung, head, and neck cancer. It shows more affinity 
(1.9-fold) for microtubules when compared with paclitaxel [5-8]. 
Despite these advantages, clinical use of docetaxel is still limited due 
to its low water solubility. It is presently marketed as TAXOTERE. RTM 
injection concentrate, due to its poor water solubility docetaxel, is 
given in a vehicle containing high concentration of Tween 80 and the 
injection needs to be diluted with 13% ethanol in water for injection. 
The presence of high concentrations of Tween 80 and ethanol causes 
severe adverse effects like several hypersensitivity reactions and it also 
shows incompatibility with common PVC intravenous administration 
sets [9,10].
It has been reported that the toxicity of DTX is mainly based on the 
formulation technique. As a result, the current investigations are 
focused on different formulation techniques like nanotechnology. 
Recently, various nanonization strategies have emerged to improve 
the dissolution rates and solubility of insoluble drugs, for example, 
polymeric nanomicelles, nanoemulsions, nanostructured lipid carriers, 
and nanocrystals, whereas in nanocrystal technology which can be 
applied to all poorly soluble drugs is the simplest and practical approach 
because all these drugs could be directly disintegrated into nanosizing 
particles [11-13]. In nanosuspensions, drugs can exist in two forms: 
Crystalline state and amorphous state: When drug particles exist in the 
form of crystalline state, they are called as nanocrystals. Nanocrystals, 
a carrier-free colloidal drug delivery system, consist essentially of 
pure drug crystals and a minimum amount of surfactants required 
for stabilization and have been applied to tackle the formulation issue 
of poorly soluble drugs. With particle size in nanometer range and 
enormous particle surface area, nanocrystals can increase the dissolution 
velocity and saturation solubility of the number of insoluble drugs, 
therefore, improving their bioavailability and biological effects [14-19].
Nanocrystals can be administered through various routes such as 
oral [20], parenteral [21], ocular [22], pulmonary [23], and dermal [24], 
as well as for targeted delivery [25]. Nanocrystals can be produced by 
bottom-up (antisolvent precipitation) and top-down (media milling, 
high-pressure homogenization, etc.) technologies or combination 
technologies and chemical synthesis [26]. Nanoprecipitation comes 
under bottom-up technique in which a poorly water-soluble drug is 
dissolved in an organic medium, which is water miscible and a pouring 
of this solution into a non-solvent, will cause precipitation of finely 
dispersed drug nanocrystals. The stabilizers which are used in the 
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formulation adsorbed on the formed drug particles to inhibit crystal 
growth [27,28].
The main objective of this study was to prepare and evaluate the 
docetaxel nanocrystals and study the effect of various stabilizers 
on the physicochemical properties and in vitro release studies. 
Characterization of DTX nanocrystals was carried out by different 
techniques such as Fourier-transform infrared spectroscopy (FTIR), 
particle size analysis, zeta potential, scanning electron microscopy 
(SEM), and drug release profile.
MATERIALS AND METHODS
Docetaxel was obtained from Ningbo Samreal Chemical Co., Ltd., 
China, povidone from BASF, polysorbate 80 from Seppic, France, and 
egg lecithin from Doosan Corporation, Korea. Poly(lactic-co-glycolic 
acid) (PLGA) was obtained from Purac Biochem, Netherlands. All the 
ingredients were analytical grade. The laboratory grade chemicals 
used for the work are ethanol, n-methylpyrrolidone, propylene glycol, 
sodium hydroxide, and potassium dihydrogen phosphate purchased 
from Merk Chemicals, Mumbai.
Preformulation study
Construction of a calibration curve by ultraviolet (UV)
About 1 mg/ml of docetaxel stock solution was prepared using isopropyl 
alcohol (IPA) and water (50:50) as mixed solvent and further dilutions 
were made with the same solvent. To a series of 10 ml volumetric 
flasks, aliquots of standard solutions were taken and the volume was 
made up to the mark. Moreover, the absorbance of all the solutions was 
measured at 231 nm. A graph was plotted by taking absorbance on 
Y-axis and concentration on X-axis.
Drug excipient compatibility study
Compatibility studies are important to select suitable excipients for any 
pharmaceutical formulation. Therefore, in the present work, a study 
was carried out using FT-IR to find out if there is any possible chemical 
interaction of drug with excipients used in the formulation.
The FTIR spectra of different nanocrystals were carried out by potassium 
bromide disc method using Tensor 27 FTIR spectrophotometer (Bruker 
Optics, Germany) in the region of 4000-600 cm−1.
Determination of partition coefficient
A partition coefficient is the ratio of concentrations of a compound in 
a mixture of two immiscible phases at equilibrium. These coefficients 
are a measure of the difference in solubility of the compound in 
two phases, i.e., hydrophilic and hydrophobic. Hence, the partition 
coefficient is measured whether the chemical substance is hydrophilic 
or hydrophobic and partition coefficient is used to estimate the 
distribution of drugs within the body. Hydrophilic drugs (low octanol/
water partition coefficients) preferentially are found in hydrophilic 
compartments such as blood serum, whereas hydrophobic drugs with 
high octanol/water partition coefficients are preferentially distributed 
to hydrophobic compartments such as lipid bilayers of cells.
The partition coefficient of docetaxel was determined in octanol/water, 
n-hexane/water, oleyl alcohol/water, and dichloromethane/water 
systems at room temperature. Equal volume of organic phase and 
aqueous phase was taken in a glass stopper graduated tube and 25 mg 
of drug was added. The mixture was then shaken using mechanical 
shaker periodically at room temperature for 24 h. Then, the mixture 
was transferred to a separating funnel and allowed to equilibrate for 
6 h. The aqueous and organic phase was separated and filtered through 
membrane filter and drug content in each phase was analyzed by UV-
visible spectrophotometer. The partition coefficient was calculated 
using the below formula.
Ko/w = Co/Cw
Preparation of docetaxel nanocrystals
Docetaxel nanocrystals were prepared by nanoprecipitation method 
using ethanol and n-methylpyrrolidone as solvents; propylene glycol as 
an antisolvent; Tween 80, povidone C-12, and egg lecithin as stabilizers; 
and PLGA as polymer. Sixteen formulations have been developed 
by using different surfactants at different concentrations as shown 
Fig. 1: Standard graph of docetaxel in isopropyl alcohol and 
phosphate buffer of pH 7.4 (50:50)
Table 1: Formulation of docetaxel nanocrystals




Quantity of Tween 
80 (or) PLGA (mg)
Molar ratio
Tween 80 F1 1 1 30.392 1:0.5
F2 1 1 60.784 1:1
F3 1 1 182.352 1:3
F4 1 1 364.704 1:6
Egg lecithin F5 1 1 18.328 1:0.5
F6 1 1 36.656 1:1
F7 1 1 109.968 1:3
F8 1 1 219.936 1:6
Povidone F9 1 1 58 1:0.5
F10 1 1 116 1:1
F11 1 1 348 1:3
F12 1 1 696 1:6
Tween 80 and PLGA F13 4 2 40 1:1:0.001
F14 4 2 80 1:1:0.003
F15 4 2 160 1:1:0.006
F16 4 2 320 1:1:0.012
PLGA: Poly (lactic-co-glycolic acid)
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in Table 1. From the results the optimized formulations have been 
identified as shown in Table 2.
In this method, the drug was dissolved in ethanol. After that, the drug 
dissolved stabilizer solution was added. This solution was mixed using 
cyclomixer at 150 rpm. To this solution, an antisolvent, i.e., propylene 
glycol was added and mixed. The resulting formulation was kept a side 
for 24 h at room temperature [29-31].
Physical characterization of docetaxel nanocrystals
Microscopic evaluation
A drop of the formulation was added in the middle of a clean slide and 
placed a coverslip. Then, place the prepared slide onto the stage of the 
microscope. Observe the shape of crystals under microscope using ×40 
eyepiece and capture the images using Motic image software.
Particle size and zeta potential
The average diameter and polydispersity index of the nanocrystals 
were determined by particle size analyzer (Horiba, nanopartica sz-100 
Table 3: Partition coefficient of docetaxel in different solvent systems
Solvent system Solvent Diluted with Concentration (µg/mL) Concentration (mg/mL) p Log p
Octanol-water Octanol IPA 10423 10.423 387.47 2.588
Water IPA+water 26.95 0.0269
Hexane-water Hexane IPA 97 0.097 3.818 0.581
Water IPA+water 25.24 0.0254
Oleyl alcohol-water Oleyl alcohol IPA 126 0.126 5.271 0.721
Water IPA+water 23.21 0.0239
Dichloromethane-water DCM IPA 17652 17.652 711.774 2.854
Water IPA+water 24.28 0.0248
IPA: Isopropyl alcohol, DCM: Dichloromethane







1 Tween 80 1:1 F2
2 Egg lecithin 1:3 F3
3 Povidone C-12 1:1 F10
4 Tween 80 and PLGA 1:1:0.001 F13
PLGA: Poly (lactic-co-glycolic acid)
Table 4: Microscopic crystal shapes of docetaxel nanocrystal formulations
Stabilizer Formulation Molar ratio Crystal structure
Tween 80 F1 1:0.5 Large, rod, and elongated cylindrical
F2 1:1 Small rods
F3 1:3 Small rods
F4 1:6 Small rods
Egg lecithin F5 1:0.5 Large clusters
F6 1:1 Irregular
F7 1:3 Irregular
F8 1:6 Large clusters
Povidone F9 1:0.5 Large elongated cylindrical
F10 1:1 Rod and cubic shaped
F11 1:3 Rob shaped
F12 1:6 Irregular
Tween 80 and PLGA F13 1:1:0.001 Irregular
F14 1:1:0.003 Physical unstable
F15 1:1:0.006 Physical unstable
F16 1:1:0.012 Physical unstable
PLGA: Poly (lactic-co-glycolic acid)
Table 5: Physicochemical characteristics of docetaxel nanocrystal formulations
Stabilizer Formulation Molar ratio Particle size (nm) PDI Zeta potential
Tween 80 F1 1:0.5 240±39.76 0.562±0.005 −30.2±2.2
F2 1:1 142.9±29.28 0.512±0.005 −31.8±1.8
F3 1:3 138.4±36.12 0.852±0.005 −24.5±2.3
F4 1:6 133.4±27.16 0.587±0.005 −18.7±2.1
Egg lecithin F5 1:0.5 346.5±19.84 0.756±0.005 −31.5±1.8
F6 1:1 289.1±26.74 0.542±0.005 −32.6±1.6
F7 1:3 174.8±25.29 0.489±0.005 −34.6±2.5
F8 1:6 523.4±18.25 0.655±0.005 −28.3±1.7
PVP F9 1:0.5 362.7±14.37 0.785±0.005 −19.8±2.2
F10 1:1 161±33.36 0.593±0.005 −29.4±2.4
F11 1:3 153.2±31.12 0.469±0.005 −22.6±1.7
F12 1:6 144.5±26.56 0.454±0.005 −23.8±2.6
Tween 80 and PLGA F13 1:1:0.001 81.0±19.89 0.726±0.005 −22.4±1.9
F14 1:1:0.003 102.23±28.37 0.534±0.005 −23.72±1.9
F15 1:1:0.006 93.56±24.16 0.812±0.005 −24.73±1.7
F16 1:1:0.012 112.34±23.81 0.413±0.005 −24.93±2.5
All determinations were performed in triplicate and values were expressed as mean±SD, (n=3). PDI: Polydispersity index, PVP: Polyvinyl pyrrolidine, SD: Standard 
deviation, PLGA: Poly (lactic-co-glycolic acid)
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series). Samples were backscattered by helium-neon laser (633 nm) 
at an angle of 90o and at a constant temperature of 25°C. Before the 
measurement, each sample was vortexed for 5 s to avoid particle 
settlement.
Zeta potential was estimated using the zetasizer (Horiba, nanopartica 
sz-100 series) which measures the particle electrophoretic mobility 
in a thermostated cell. All the samples were analyzed 24 h after their 
preparation.
Crystal morphology
Shape and surface morphology of nanoparticles were done by SEM; 
small volume of nanoparticulate suspension was placed on an electron 
microscope brass stub. The stubs were placed briefly in a drier and then 
coated with gold in an ion sputter. Pictures of nanoparticles were taken by 
random scanning of the stub. The shape and surface morphology of the 
nanoparticles were determined from the photomicrographs of each batch.
Docetaxel assay
A standard and sample solution were prepared, inject separately 
20 μl of the standard and sample solution in chromatographic condition 
and record the chromatogram. Calculate the content of drug per ml in 
liposomal injection as follows:
Assay = As/Ar × Cr/Cs × P
Where,
AS = Area corresponding to docetaxel peak in the sample
AR = Area corresponding to docetaxel peak in the working standard
CR = Concentration of docetaxel in working standard
CS = Concentration of docetaxel in sample
P = Percentage purity of working standard.
In vitro dissolution of docetaxel nanocrystals
The in vitro release of formulations carried out by membrane 
diffusion technique using dialysis sack of molecular weight cutoff 
Fig. 2: Fourier-transform infrared spectroscopy spectrum of docetaxel
Fig. 3: Fourier-transform infrared spectroscopy spectrum of docetaxel and povidone physical mixture
Table 7: Release rate profile of formulations F2, F7, F10, and F13
Formulation Zero order First order Higuchi Korsmeyer–Peppas
R2 R2 R2 R2 n
Tween 80 (F2) 0.993 0.970 0.924 0.996 1.020
Egg lecithin (F7) 0.849 0.984 0.998 0.975 1.031
PVP (F10) 0.836 0.994 0.998 0.973 1.055
PLGA (F13) 0.968 0.735 0.767 0.929 0.827
*PVP: Polyvinyl pyrrolidine, PLGA: Poly (lactic-co-glycolic acid)
Table 6: Assay of formulations F2, F7, F10, and F13





All determinations were performed in triplicate and values were expressed as 
mean±SD, n=3. SD: Standard deviation
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1000. Membrane was soaked in water for 30 min to remove traces of 
preservative and tied to one end of the glass test tube which constituted 
donor compartment. 2 ml of the formulation was transferred to donor 
compartment and placed into receptor compartment of 400 mL of 
phosphate buffer with Tween 80 maintained at a temperature of 37°C 
and rotated at 300 rpm using a magnetic stir bar. At specified time 
points, the samples were withdrawn and replaced with fresh buffer 
immediately after sampling. These samples were filtered through 
0.45 μm membrane filter and analyzed spectrophotometrically at 
231 nm after suitable dilution if necessary, using appropriate blank.
Solubility studies
Selected nanocrystal formulations solubility was determined in pH 7.4 
buffer. An excess amount of nanocrystal formulation was added into 
50 ml of the solvent. The mixture was stirred in a mechanical shaker for 
24 h. The mixture was then filtered and filtrate was diluted suitably to 
determine the solubility of drug.
Stability studies
The stability of a pharmaceutical delivery system may be defined as 
the capability of a particular formulation, in a specific container. The 
short-term stability was conducted to monitor physical and chemical 
Fig. 4: Microscopic images of optimized formulations
Fig. 5: Comparison of in vitro release studies for optimized 
formulations F2, F7, F10, and F13
Fig. 6: Zero-order release studies for optimized formulations F2, 
F7, F10, and F13
Fig. 7: First-order release studies for optimized formulations F2, 
F7, F10, and F13
Fig. 8: Higuchi’s order plot for optimized formulations F2, F7, F10, 
and F13
Fig. 9: Korsmeyer–Peppas model for optimized formulations F2, 
F7, F10, and F13
Table 8: Solubility profile of docetaxel nanocrystal optimized 
formulations
Serial number Formulation Solubility (µg/mL)





All determinations were performed in triplicate and values were expressed as 
mean±SD, n=3. SD: Standard deviation
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stabilities of the liquid form of docetaxel nanocrystal formulations 
at 25°C ± 2°C and 60% ± 5% RH for up to 3 months. The stability 
parameter, such as assay, was determined as function of the storage 
time.
RESULTS AND DISCUSSION
Standard curve of docetaxel in UV spectrophotometer
The UV absorbance of DTX standard solution is in the range of 
10–40 µg/ml of drug in IPA and buffer pH 7.4 (50:50) showed 
linearity at λ max 231 nm. The linearity was plotted for absorbance 
against concentration with R2 value 0.999 and with the slope 
equation y = 0.018x-0.006. The standard curve of DTX is shown in 
Fig. 1.
Compatibility studies
The compatibility between the drug and excipients was evaluated 
using FTIR peak matching method. There was no appearance or 
disappearance of peaks in the drug-povidone mixture as evident from 
Figs. 2 and 3, which confirmed the absence of any chemical interaction 
between the drug and povidone. Compatibility of docetaxel with other 
ingredients was proved by stability studies.
Partition coefficient
The partition coefficient of paclitaxel was performed in different solvent 
systems and the results are shown in Table 3.
Physicochemical characterization
Microscopic evaluation
Different shaped crystals were observed in all the formulations as given 
in Table 4. In case of F14, F15, and F16 as the polymer concentration 
increases, the clarity of formulations was decreased, due to the 
increase in viscosity due to its high molecular weight. It was observed 
that the shape and size of the crystals were changed with the type and 
concentration of stabilizer [Fig. 4].
Particle size and zeta potential
The particle size distribution and zeta potential were analyzed for 
all formulations of DTX nanocrystals. In Tween 80 formulations, the 
optimum values were found in 1:1 ratio, in case of egg lecithin, it was 
1:3 ratios, whereas in povidone, it was again 1:1 ratio, and in case of 
PLGA, it was 1:1:0.001 ratio. Particle size of all formulations was found 
to be in the nanometer range and a sufficiently high zeta potential value 
indicates that the formulations would be stable and the tendency to 
agglomerate would be miniscule [Table 5].
Assay
The assay value is determined for all the formulations. The assay value 
is within the limit (90%–110%) for all the formulations, the results are 
shown in Table 6.
In vitro dissolution data
The in vitro dissolution profile of prepared formulations was determined 
by membrane diffusion method. The dissolution was carried out for a 
period of 168 h in 7.4 pH phosphate buffer with 6% Tween 80.
The cumulative percent release of F2, F7, F10, and F13 formulations 
at various time intervals was calculated. The cumulative percent 
drug release in four formulations was plotted against time in Fig. 5. 
Cumulative percentage drug released for F2 after 96 h was more, i.e., 
100%, followed by F10 was 90.213% and for F7 was 84.312%, whereas 
in case of F13, the cumulative percentage drug released after 96 h 
was only 51.799 and reached 97.987% after 168 h. It was evident that 
the drug release from the F13 formulation decreased compared with 
the other three formulations. It was suggesting that the presence of 
polymer sustained the drug release.
Release kinetics
The release kinetics of F3, F6, and F9 formulations was studied. Based 
on the highest regression [r2] values, the best-fit model for F2 and F 
13 was zero order and for F7 and F10 was Higuchi diffusion model. 
All the formulations were then fitted into Korsmeyer–Peppas model 
and n values were reported. For F2, F7, and F10, it was > 1 indicates 
super case-II transport and for F13, it was < 0.89 indicates non-Fickian 
diffusion. The results are shown in Figs. 6-9 and Table 7.
Solubility studies
The solubility studies for pure drug and formulations were carried out 
in the PBS and the results are shown in Table 8. In four formulations, the 
solubility was increased 4 times when compared with the pure drug. 
This increased solubility can be attributed to enhanced dissolution of 
drug in nanocrystalline state.
Stability data
The stability of the docetaxel nanocrystals was evaluated after storage at 
2–8°C and 25°C for 90 days. The assays of the samples were determined 
as a function of the storage time. The nanocrystals stored at 2–8°C were 
found to be stable for the duration of 90 days. The results are shown in 
Tables 9 and 10.
Table 9: Stability data at 2–8°C
Formulation code Time points (days)
0 (%) 15 (%) 30 (%) 40 (%) 60 (%) 90 (%)
F2 103.3±0.96 102.1±0.73 101.6±1.12 100.8±0.43 99.8±0.96 98.5±0.96
F7 101.7±0.65 100±0.37 99.1±0.12 98.4±1.1 98.1±0.65 97.8±0.65
F10 104±1.3 101.5±1.0 99.7±0.9 99.2±0.63 98.7±1.3 97.7±1.7
F13 102±0.21 101.3±0.02 100±1.23 99.2±1.45 99.1±0.28 98.3±1.0
All determinations were performed in triplicate and values were expressed as mean±SD, n=3. SD: Standard deviation
Table 10: Stability data at 25°C
Formulation code Time points (days)
0 (%) 15 (%) 30 (%) 40 (%) 60 (%) 90 (%)
F2 103.3±0.96 101.8±0.33 101±1.15 100.1±0.83 98.1±0.96 96.1±0.16
F7 101.7±0.65 100±0.37 99.1±0.12 98.4±1.1 97.1±0.65 95.8±0.65
F10 104±1.3 102.5±1.2 100.7±0.4 100.2±0.23 99.5±1.7 97.1±1.5
F13 102±0.21 102±0.11 100.2±1.22 99.2±0.93 98.5±1.23 97.1±0.23
All determinations were performed in triplicate and values were expressed as mean±SD, n=3. SD: Standard deviation
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CONCLUSION
From the executed experimental results, it could be concluded that the 
Tween 80, egg lecithin, and povidone are the suitable stabilizers for the 
docetaxel nanocrystal formulation. The shape and size of the crystals 
were changed with the type and concentration of stabilizer. Addition of 
PLGA further reduces the particle size and sustained the drug release. 
Although the preliminary data based on in vitro dissolution profile, 
release kinetics and stability studies proved that the suitability of such 
formulations, still a thorough experiment will be required based on the 
animal studies. Thereafter, we can find the actual mode of action of this 
kind of dosage form.
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